tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Nail Diseases D009260 2 associated lipids
Paronychia D010304 3 associated lipids
Duodenal Ulcer D004381 12 associated lipids
Dyspnea D004417 10 associated lipids
Vascular Diseases D014652 16 associated lipids
Heart Defects, Congenital D006330 20 associated lipids
Listeriosis D008088 12 associated lipids
Connective Tissue Diseases D003240 2 associated lipids
Ascites D001201 25 associated lipids
Albuminuria D000419 18 associated lipids
Anemia D000740 21 associated lipids
Osteomalacia D010018 5 associated lipids
Tremor D014202 15 associated lipids
Pemphigoid, Bullous D010391 8 associated lipids
Vasculitis D014657 14 associated lipids
Hypothermia D007035 19 associated lipids
Parkinson Disease D010300 53 associated lipids
Down Syndrome D004314 18 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Keloid D007627 12 associated lipids
Nephritis D009393 19 associated lipids
Food Hypersensitivity D005512 7 associated lipids
Respiration Disorders D012120 5 associated lipids
Thymus Neoplasms D013953 15 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Facial Neoplasms D005153 3 associated lipids
Dysgammaglobulinemia D004406 3 associated lipids
Influenza, Human D007251 11 associated lipids
Immune System Diseases D007154 3 associated lipids
Headache D006261 4 associated lipids
Cystitis D003556 23 associated lipids
Sarcoma, Kaposi D012514 6 associated lipids
HIV Infections D015658 20 associated lipids
Drug Eruptions D003875 30 associated lipids
Folliculitis D005499 7 associated lipids
Blindness D001766 6 associated lipids
Oliguria D009846 2 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Graves Disease D006111 6 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Gout D006073 4 associated lipids
Papillomavirus Infections D030361 4 associated lipids
Choline Deficiency D002796 16 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Biliary Fistula D001658 13 associated lipids
Glomerulonephritis, Membranoproliferative D015432 3 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Renal Insufficiency D051437 8 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Hyperparathyroidism, Secondary D006962 4 associated lipids
Neuritis D009443 4 associated lipids
Hypertension, Portal D006975 12 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Hepatitis C D006526 7 associated lipids
Lichen Planus D008010 3 associated lipids
Sclerosis D012598 5 associated lipids
Atherosclerosis D050197 85 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Insulin Resistance D007333 99 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Diabetes Complications D048909 4 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Dental Pulp Calcification D003784 2 associated lipids
Hepatitis C, Chronic D019698 12 associated lipids
Coronary Stenosis D023921 6 associated lipids
Dehydration D003681 11 associated lipids
Hemophilia A D006467 10 associated lipids
Encephalitis D004660 15 associated lipids
Dyslipidemias D050171 7 associated lipids
Fatigue D005221 10 associated lipids
Meningoencephalitis D008590 4 associated lipids
Gynecomastia D006177 6 associated lipids
Thyroiditis, Autoimmune D013967 9 associated lipids
Myxedema D009230 2 associated lipids
Pregnancy Complications D011248 19 associated lipids
Candidiasis, Oral D002180 11 associated lipids
Stomatitis D013280 14 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Lung Diseases, Interstitial D017563 5 associated lipids
Weight Loss D015431 56 associated lipids
Tinea D014005 5 associated lipids
Critical Illness D016638 13 associated lipids
Endotoxemia D019446 27 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Memory Disorders D008569 33 associated lipids
Glucose Intolerance D018149 13 associated lipids
Dry Eye Syndromes D015352 10 associated lipids
Thinness D013851 11 associated lipids
Opportunistic Infections D009894 8 associated lipids
Eczema D004485 4 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Vasculitis, Leukocytoclastic, Cutaneous D018366 5 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Lupus Nephritis D008181 8 associated lipids
Telangiectasis D013684 2 associated lipids
Anemia, Iron-Deficiency D018798 6 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Matsuura T et al. Blockade of interleukin-2 production from cloned T cells by cyclosporine and FK 506 assessed by proliferation assays in vitro. 1992 Transplant. Proc. pmid:1371623
Okamura N et al. Enhanced liver regeneration by FK 506 can be blocked by interleukin-1 alpha and interleukin-2. 1992 Transplant. Proc. pmid:1371624
Sakr M et al. Effect of renal ischemia on plasma levels of FK 506 in rats. 1992 Transplant. Proc. pmid:1371625
Schreiber SL and Crabtree GR The mechanism of action of cyclosporin A and FK506. 1992 Immunol. Today pmid:1374612
Demetris AJ et al. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. 1992 Transplantation pmid:1374944
Bundick RV et al. FK506 as an agonist to induce inhibition of interleukin 2 production. 1992 Transplantation pmid:1374947
Masutani H et al. Suppression of the histologic changes of GVHD by FK 506 in rat small bowel transplantation. 1992 Transplant. Proc. pmid:1376519
Santiago SF et al. Effect of short-term immunosuppressive therapy with FK 506 or CyA on the donor in small intestine allotransplantation in rats. 1992 Transplant. Proc. pmid:1376520
Utsunomiya H et al. Effect of FK 506 on orthotopic small bowel transplantation in rats. 1992 Transplant. Proc. pmid:1376521
Lemster B et al. Cytokine gene expression in murine lymphocytes activated in the presence of FK 506, bredinin, mycophenolic acid, or brequinar sodium. 1992 Transplant. Proc. pmid:1281576
Tze WJ et al. FK 506: an effective immunosuppressant for islet xenotransplantation. 1992 Transplant. Proc. pmid:1281577
Kamei T et al. Established intraportal islet allograft is rejected despite the acceptance of donor-specific second cardiac allograft. 1992 Transplant. Proc. pmid:1281579
Woo J et al. FK 506 treatment following syngeneic bone marrow transplantation does not inhibit clonal deletion of V beta 5+ or V beta 11+ T cells. 1992 Transplant. Proc. pmid:1281583
Schreiber SL Immunophilin-sensitive protein phosphatase action in cell signaling pathways. 1992 Cell pmid:1379518
Aldape RA et al. Charged surface residues of FKBP12 participate in formation of the FKBP12-FK506-calcineurin complex. 1992 J. Biol. Chem. pmid:1379588
Langrehr JM et al. Nitric oxide production in host-versus-graft and graft-versus-host reactions in the rat. 1992 J. Clin. Invest. pmid:1379617
Van Thiel DH et al. FK 506 reduces the injury experienced following renal ischemia and reperfusion. 1992 Ren Fail pmid:1380720
Bolton C The efficacy of cyclosporin A, FK-506 and prednisolone to modify the adoptive transfer of experimental allergic encephalomyelitis (EAE). 1992 Agents Actions pmid:1380765
Terada N et al. Rapamycin inhibits the phosphorylation of p70 S6 kinase in IL-2 and mitogen-activated human T cells. 1992 Biochem. Biophys. Res. Commun. pmid:1380801
Griffin AD et al. FK 506 in canine renal transplantation. 1992 Transplant. Proc. pmid:1384209
Griffiths RJ et al. Characterisation of passively transferred antigen arthritis induced by methylated bovine serum albumin in the rat: effect of FK 506 on arthritis development. 1992 Agents Actions pmid:1384284
Todo S et al. Intestinal transplantation in composite visceral grafts or alone. 1992 Ann. Surg. pmid:1384443
Massol N et al. Rabbit FKBP59-heat shock protein binding immunophillin (HBI) is a calmodulin binding protein. 1992 Biochem. Biophys. Res. Commun. pmid:1384470
Jordan ML et al. Initial studies with FK506 in renal transplantation. 1991 Sep-Oct Cleve Clin J Med pmid:1718631
Blackham A and Griffiths RJ The effect of FK506 and cyclosporin A on antigen-induced arthritis. 1991 Clin. Exp. Immunol. pmid:1718639
Carobbi A et al. Effect of splenectomy in combination with FK 506 and 15-deoxyspergualin on cardiac xenograft survival. 1991 Transplant. Proc. pmid:1703704
Fukuda T et al. Inhibition of antigen-induced late asthmatic response and bronchial hyperresponsiveness by cyclosporin and FK 506. 1991 Int. Arch. Allergy Appl. Immunol. pmid:1718889
Murase N et al. FK 506 prevents spontaneous diabetes in the BB rat. 1991 Transplant. Proc. pmid:1703705
Meiser BM et al. Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. 1991 Lancet pmid:1719321
Watanabe K et al. Donor bone marrow cell facilitates induction of tolerance to kidney allografts in dogs treated with fractionated lymphoid irradiation and FK 506. 1991 Transplant. Proc. pmid:1703706
Abu-Elmagd KM et al. Strategy of FK 506 therapy in liver transplant patients: effect of graft function. 1991 Transplant. Proc. pmid:1721272
Ericzon BG et al. Pharmacokinetics of FK 506 during maintenance therapy in liver transplant patients. 1991 Transplant. Proc. pmid:1721273
Jain AB et al. Pharmacokinetics of cyclosporine and nephrotoxicity in orthotopic liver transplant patients rescued with FK 506. 1991 Transplant. Proc. pmid:1721274
McMichael J et al. Evaluation of a novel "intelligent" dosing system for optimizing FK 506 therapy. 1991 Transplant. Proc. pmid:1721275
Ali Shah I et al. Effects of FK 506 on human hepatic microsomal cytochrome P-450-dependent drug metabolism in vitro. 1991 Transplant. Proc. pmid:1721276
Moochhala SM et al. Inhibition of drug metabolism in rat and human liver microsomes by FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1721277
Connelly PR Thermodynamics of interaction of FK 506-binding protein and its ligands. 1991 Transplant. Proc. pmid:1721304
Donnelly JG and Soldin SJ Purification of a 50- to 58-kDa immunophilin from human spleen and a Jurkat T-cell line capable of binding cyclosporine A, FK 506, and rapamycin. 1991 Transplant. Proc. pmid:1721305
Rosborough SL et al. Identification of FKBP-related proteins with antibodies of predetermined specificity and isolation by FK 506 affinity chromatography. 1991 Transplant. Proc. pmid:1721306
Zeevi A et al. In vitro assessment of FK 506 immunosuppressive activity in transplant patients. 1991 Transplant. Proc. pmid:1721307
Katz HR et al. Mast cell biochemical and functional heterogeneity. 1991 Transplant. Proc. pmid:1721308
de Paulis A et al. Antiinflammatory effect of FK 506 on human basophils. 1991 Transplant. Proc. pmid:1721309
Su MS and Semerjian A Activation of transcription factor NF kappa B in Jurkat cells is inhibited selectively by FK 506 in a signal-dependent manner. 1991 Transplant. Proc. pmid:1721310
Lewis WD et al. FK 506 rescue therapy in liver transplant recipients with drug-resistant rejection. 1991 Transplant. Proc. pmid:1721336
Woodle ES et al. FK 506: reversal of humorally mediated rejection following ABO-incompatible liver transplantation. 1991 Transplant. Proc. pmid:1721337
Shaw BW et al. FK 506 for rescue treatment of acute and chronic rejection in liver allograft recipients. 1991 Transplant. Proc. pmid:1721338
McDiarmid SV et al. FK 506 rescue therapy in liver transplantation: outcome and complications. 1991 Transplant. Proc. pmid:1721339
Rucay P et al. FK 506 rescue therapy for refractory acute rejection in five liver recipients. 1991 Transplant. Proc. pmid:1721340
Macleod AM and Thomson AW FK 506: an immunosuppressant for the 1990s? 1991 Lancet pmid:1702172
Reding R et al. Compassionate use of FK 506 in pediatric liver transplantation: a pilot study. 1991 Transplant. Proc. pmid:1721341
Darras FS et al. Transplantation of pediatric en bloc kidneys under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721368
Shapiro R et al. Kidney transplantation under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1703352
Todo S et al. Clinical small bowel or small bowel plus liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1721369
Tzakis AG et al. Use of FK 506 in pediatric patients. 1991 Transplant. Proc. pmid:1703353
Fries D et al. Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation. 1991 Transplant. Proc. pmid:1721370
Jain AB et al. Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1703354
Wijnen RM et al. Toxicity of FK 506 in the cynomolgus monkey: noncorrelation with FK 506 serum levels. 1991 Transplant. Proc. pmid:1721371
Venkataramanan R et al. Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1703355
Fung JJ et al. Adverse effects associated with the use of FK 506. 1991 Transplant. Proc. pmid:1721372
Omar G et al. FK 506 inhibition of cyclosporine metabolism by human liver microsomes. 1991 Transplant. Proc. pmid:1703356
Hebert MF et al. Efficacy and toxicity of FK 506 for the treatment of resistant rejection in liver transplant patients. 1991 Transplant. Proc. pmid:1721373
Eiras G et al. Effects of FK 506 and cyclosporine on T-cell activation: integrin-mediated adhesion of T cells, proliferation, and maturation of cytotoxic T cells. 1991 Transplant. Proc. pmid:1703357
DiMartini A et al. Psychiatric morbidity in liver transplant patients. 1991 Transplant. Proc. pmid:1721399
Lopez OL et al. Neuropathologic findings in liver transplantation: a comparative study of cyclosporine and FK 506. 1991 Transplant. Proc. pmid:1721400
Viebahn R et al. Hypoxic and reoxygenation injury in human and rat hepatocytes--influence of FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1721401
Morrisett JD et al. Effect of FK 506 and cyclosporine on plasma cholesterol levels in rabbits. 1991 Transplant. Proc. pmid:1721402
Jacobs TW et al. The effect of FK 506, cyclosporine A, and cyclosporine G on serum 1,25-dihydroxyvitamin D levels. 1991 Transplant. Proc. pmid:1721403
Abu-Elmagd KM et al. Acute hemolytic anemia in liver and bone marrow transplant patients under FK 506 therapy. 1991 Transplant. Proc. pmid:1721404
Adams CK and Famili P A study of the effects of the drug FK 506 on gingival tissues. 1991 Transplant. Proc. pmid:1721405
Gotoh M et al. Tolerance induction by liver grafting and FK 506 treatment in nonhuman primates. 1991 Transplant. Proc. pmid:1721431
Valdivia LA et al. Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721432
Wu GD et al. FK 506 inhibits the development of transplant arteriosclerosis. 1991 Transplant. Proc. pmid:1721433
Kobayashi N et al. Effect of FK 506 on abdominal organ cluster transplantation in pigs. 1991 Transplant. Proc. pmid:1721434
Holechek MJ Medication review: FK 506. 1991 ANNA J pmid:1708982
Wada H et al. An attempt to induce tolerance to skin grafts in congenic mice with FK 506. 1991 Transplant. Proc. pmid:1721435
Michnick SW et al. Solution structure of FKBP, a rotamase enzyme and receptor for FK506 and rapamycin. 1991 Science pmid:1709301
Kuroki H et al. Synergistic effect of FK 506 and donor-specific blood transfusion on rat skin but not on composite tissue (limb) allograft survival. 1991 Transplant. Proc. pmid:1721436
Van Duyne GD et al. Atomic structure of FKBP-FK506, an immunophilin-immunosuppressant complex. 1991 Science pmid:1709302
Lim SM and White DJ The pharmacology of immunosuppression. 1991 Ann. Acad. Med. Singap. pmid:1709344
Rosen MK et al. Proton and nitrogen sequential assignments and secondary structure determination of the human FK506 and rapamycin binding protein. 1991 Biochemistry pmid:1709363
Sakr MF et al. FK 506 ameliorates the hepatic injury associated with ischemia and reperfusion in rats. 1991 Hepatology pmid:1709412
McManus BM et al. Impact of FK 506 on myocarditis in the enteroviral murine model. 1991 Transplant. Proc. pmid:1721463
Nossal GJ Summary of the First International FK 506 Congress: perspectives and prospects. 1991 Transplant. Proc. pmid:1721464
Staruch MJ et al. Differential effects of the immunosuppressive macrolides FK-506 and rapamycin on activation-induced T-cell apoptosis. 1991 Int. J. Immunopharmacol. pmid:1721613
Abu-Elmagd K et al. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. 1991 Transplantation pmid:1713365
Matsuura T et al. [Experimental studies on the mode of action of cyclosporine and FK506 assessed by proliferation response of human cloned T lymphocytes]. 1991 Hinyokika Kiyo pmid:1721767
Takada K et al. Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. 1991 J. Pharmacobio-dyn. pmid:1713626
Morris PJ Cyclosporine, FK-506 and other drugs in organ transplantation. 1991 Curr. Opin. Immunol. pmid:1721824
Jin YJ et al. Molecular cloning of a membrane-associated human FK506- and rapamycin-binding protein, FKBP-13. 1991 Proc. Natl. Acad. Sci. U.S.A. pmid:1713687
Lhoëst G et al. Isolation and mass spectrometric identification of five metabolites of FK-506, a novel macrolide immunosuppressive agent, from human plasma. 1991 Pharm Acta Helv pmid:1722046
Murase N et al. Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. 1991 Surgery pmid:1714104
Nicoletti F et al. FK-506 prevents diabetes in diabetes-prone BB/Wor rats. 1991 Int. J. Immunopharmacol. pmid:1722192
Lodish HF and Kong N Cyclosporin A inhibits an initial step in folding of transferrin within the endoplasmic reticulum. 1991 J. Biol. Chem. pmid:1714445
Ellis D et al. Phospholipase-C and Na-K ATPase activation by cyclosporine and FK506 in LLC-PK1, cells. Possible implications in blood pressure regulation. 1991 Transplantation pmid:1714643
Simmons RL and Wang SC New horizons in immunosuppression. 1991 Transplant. Proc. pmid:1714645
Lane WS et al. Complete amino acid sequence of the FK506 and rapamycin binding protein, FKBP, isolated from calf thymus. 1991 J. Protein Chem. pmid:1718307
Goto S et al. Effect of FK 506 and cyclosporine on heart allograft survival in rats. 1991 Transplant. Proc. pmid:1703700
James DG Which immunomodulator? 1991 Br J Clin Pract pmid:1718384
Flavin T et al. Initial experience with FK 506 as an immunosuppressant for nonhuman primate recipients of cardiac allografts. 1991 Transplant. Proc. pmid:1703701
Jiang H et al. Effect of FK 506 on heart allograft survival in highly sensitized recipient rats in comparison with cyclosporine. 1991 Transplant. Proc. pmid:1703702